About Vladonix
Short peptide complex penetrates cell nuclei and modulates gene expression in thymic and T-lymphocyte cells. Promotes T-cell maturation, normalizes CD4/CD8 ratios, and supports cytokine balance.
A short peptide bioregulator derived from thymus tissue, developed by the Khavinson Institute in St. Petersburg. Designed to restore thymus function and normalize immune activity in aging populations where thymic involution has reduced immune competence.
Research Areas
Regulatory & Evidence
Risk Profile
Generally considered lower risk in research contexts. Risk profile varies by individual — review contraindications before use.
Regulatory Status
- Availability Status
- Research Only
Regulatory status reflects publicly available information and may change. This is not legal or medical advice.
Safety Notes
Generally considered lower risk in research contexts. Individual response varies — review all considerations before use.
Reported contraindications & considerations
Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.
Where to Find Vladonix
1 providerClinics
1 providerFrequently Asked Questions — Vladonix
A short peptide bioregulator derived from thymus tissue, developed by the Khavinson Institute in St. Petersburg.
immune restoration, T-cell support, thymic function, longevity, anti-aging.
1 provider in the directory currently offers Vladonix.